Stock AGN ALGERNON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Market Closed - Canadian Securities Exchange
Other stock markets
 16:58:21 31/05/2024 BST 		5-day change 1st Jan Change
0.16 CAD +3.23% Intraday chart for Algernon Pharmaceuticals Inc. -.--% +146.15%
04-30 Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
04-10 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset
CI
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.
CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023
CI
Algernon Pharmaceuticals Increased Private Placement
MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast
MT
Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
CI
Algernon Pharma in LOI For Acquisition of its Chronic Cough Research Program For US$2 Million and 20% Equity Stake
MT
Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity Position
MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
CI
Algernon Pharmaceuticals Engage Maxim Group to Explore Spin-Off of Ifenprodil Phase 2 Chronic Cough Drug Development Program
MT
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
MT
Algernon Pharmaceuticals Reports Completion of Highest Planned Single Dose in DMT Phase 1 Trial
MT
Algernon Pharmaceuticals Brief: Announcing "Successful" Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Algernon Pharmaceuticals Inc.
  5. Highlights